Evox Therapeutics Completes £35.5 Million Series B Financing

Monday, September 3, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

OXFORD, England, September 3, 2018 /PRNewswire/ --

Proceeds will

advance transformative exosome therapeutics pipeline towards the clinic 

Continued expansion of world-leading exosome platform for delivery of different drug modalities

 

Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, today announces that it has raised £35.5 million ($45.4 million) of new capital in a Series B financing round.

Redmile Group led the financing with significant new investments from GV (formerly Google Ventures) and Cowen Healthcare Investments, alongside investments from Panacea Healthcare Venture, Borealis Ventures, and a small number of private investors. Existing investors, Oxford Sciences Innovation (OSI) and Oxford University also participated in this financing round. Evox had previously secured £10 million as part of a Series A seed financing from OSI.

Proceeds from this financing will support the advancement of Evox's exosome-based therapeutics pipeline, including progression of several proprietary rare disease assets towards the clinic, and continued development of its world-leading exosome drug platform.

Evox is engineering exosomes, the body's natural vesicular delivery system, to enable a wide variety of drugs to reach previously inaccessible tissues and compartments, such as crossing the blood brain barrier to deliver drugs to the central nervous system, intracellular delivery of biologics, and extra-hepatic delivery of RNA therapeutics. Evox is developing its own proprietary pipeline of exosome-based therapeutics for the treatment of rare, life-threatening diseases with significant unmet need. Evox also continues to form partnerships with major pharmaceutical companies to fully exploit the use of exosome-based therapeutics for the treatment of a wide variety of other diseases.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented: "We are very pleased for the support of both our existing and new investors who participated in this Series B financing. Over the past several years we have continued to expand the reach of our exosome platform, translating that knowledge into impactful therapeutics for our internal pipeline and for partners. We have also vigorously expanded our robust intellectual property portfolio, built our internal R&D teams, and put in place advisory boards who are offering deep insights as we advance key programmes towards clinical development.

"We are excited by the inherent transformational potential of our exosome technology, which significantly improves and enables the delivery of a wide range of therapeutic molecules, including antibodies, proteins, nucleic acids, and small molecules. This additional funding will enable us to advance our pipeline of novel exosome-based therapeutics towards the clinic and allow continued expansion of our world-leading exosome platform."

Jeremy Green, Founder & Portfolio Manager of Redmile Group, said: "We believe exosomes represent an important emerging therapeutic approach with potentially broad applicability, and we are enthusiastic to partner with the Evox team."

About Evox Therapeutics  

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox's mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.

For further information visit: http://www.evoxtherapeutics.com

SOURCE Evox Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store